BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shah NB, Haydek J, Slaughter J, Ashton JR, Zuckerman AD, Wong R, Raffa F, Garrett A, Duley C, Annis K, Wagnon J, Gaines L, Dalal R, Scoville E, Beaulieu DB, Schwartz D, Horst SN. Risk Factors for Medication Nonadherence to Self-Injectable Biologic Therapy in Adult Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis 2020;26:314-20. [PMID: 31671188 DOI: 10.1093/ibd/izz253] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Barnes EL, Loftus EV Jr, Kappelman MD. Effects of Race and Ethnicity on Diagnosis and Management of Inflammatory Bowel Diseases. Gastroenterology 2021;160:677-89. [PMID: 33098884 DOI: 10.1053/j.gastro.2020.08.064] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
2 Goodsall TM, Han S, Bryant RV. Understanding attitudes, concerns, and health behaviors of patients with inflammatory bowel disease during the coronavirus disease 2019 pandemic. J Gastroenterol Hepatol 2021;36:1550-5. [PMID: 33063927 DOI: 10.1111/jgh.15299] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
3 Rhudy C, Perry CL, Singleton M, Talbert J, Barrett TA. Chronic opioid use is associated with early biologic discontinuation in inflammatory bowel disease. Aliment Pharmacol Ther 2021;53:704-11. [PMID: 33497484 DOI: 10.1111/apt.16269] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Siegmund B. Janus Kinase inhibitors in the New Treatment Paradigms of Inflammatory Bowel Disease. J Crohns Colitis 2020;14:S761-6. [PMID: 31922534 DOI: 10.1093/ecco-jcc/jjaa003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
5 Wei S, Sollano J, Hui YT, Yu W, Santos Estrella PV, Llamado LJQ, Koram N. Epidemiology, burden of disease, and unmet needs in the treatment of ulcerative colitis in Asia. Expert Review of Gastroenterology & Hepatology 2021;15:275-89. [DOI: 10.1080/17474124.2021.1840976] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Schultheiss JPD, Altena S, Clevers MR, Baas D, Jharap B, Fidder HH. Adherence to Adalimumab Was Not Improved by a Reminder-Based Intervention with an Electronic Needle Container. Dig Dis Sci 2021;66:1477-87. [PMID: 32556818 DOI: 10.1007/s10620-020-06395-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Niccum B, Moninuola O, Miller K, Khalili H. Opioid Use Among Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2021;19:895-907.e4. [PMID: 32835841 DOI: 10.1016/j.cgh.2020.08.041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
8 Zuckerman AD, DeClercq J, Choi L, Cowgill N, McCarthy K, Lounsbery B, Shah R, Kehasse A, Thomas K, Sokos L, Stutsky M, Young J, Carter J, Lach M, Wise K, Thomas TT, Ortega M, Lee J, Lewis K, Dura J, Gazda NP, Gerzenshtein L, Canfield S. Adherence to self-administered biologic disease-modifying antirheumatic drugs across health-system specialty pharmacies. Am J Health Syst Pharm 2021:zxab342. [PMID: 34407179 DOI: 10.1093/ajhp/zxab342] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Zuckerman AD, Shah NB, Peter ME, Jolly JA, Kelley TN. Development, implementation, and evaluation of a health outcomes and research program at an integrated health-system specialty pharmacy. Am J Health Syst Pharm 2021;78:972-81. [PMID: 33693451 DOI: 10.1093/ajhp/zxab082] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Yanai H, Levine A, Hirsch A, Boneh RS, Kopylov U, Eran HB, Cohen NA, Ron Y, Goren I, Leibovitzh H, Wardi J, Zittan E, Ziv-Baran T, Abramas L, Fliss-Isakov N, Raykhel B, Gik TP, Dotan I, Maharshak N. The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial. Lancet Gastroenterol Hepatol 2021:S2468-1253(21)00299-5. [PMID: 34739863 DOI: 10.1016/S2468-1253(21)00299-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Nieto JC, Arajol C, Carmona L, Marras C, Cea-Calvo L. Adherence to subcutaneous biological therapies in patients with inflammatory rheumatic diseases and inflammatory bowel disease: a systematic review. Immunotherapy 2021;13:433-58. [PMID: 33557600 DOI: 10.2217/imt-2021-0011] [Reference Citation Analysis]